StockNews.com Initiates Coverage on Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

StockNews.com started coverage on shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) in a research report issued to clients and investors on Tuesday. The firm set a “buy” rating on the stock.

A number of other analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research note on Tuesday, January 11th. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and decreased their price target for the stock from $32.40 to $30.30 in a report on Friday, February 11th. Societe Generale cut their price objective on Fresenius Medical Care AG & Co. KGaA from €61.00 ($64.21) to €57.00 ($60.00) in a research report on Friday, February 25th. JPMorgan Chase & Co. raised their price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.26) to €51.00 ($53.68) and gave the company an “underweight” rating in a research report on Thursday, May 5th. Finally, Oddo Bhf upgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperform” rating and set a €72.00 ($75.79) price target for the company in a research report on Tuesday, March 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $51.63.

Shares of FMS stock opened at $30.16 on Tuesday. The company’s 50-day moving average price is $32.48 and its 200-day moving average price is $32.59. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 0.51. The stock has a market cap of $17.67 billion, a price-to-earnings ratio of 17.23, a PEG ratio of 1.20 and a beta of 1.17. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $28.75 and a twelve month high of $42.45.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) last posted its earnings results on Tuesday, February 22nd. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.01. The company had revenue of $5.31 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.91% and a return on equity of 6.99%. As a group, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.99 EPS for the current year.

A number of large investors have recently bought and sold shares of FMS. Ellevest Inc. increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 96.6% during the 4th quarter. Ellevest Inc. now owns 1,148 shares of the company’s stock valued at $37,000 after acquiring an additional 564 shares during the last quarter. Liberty Wealth Management LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 71.9% during the 3rd quarter. Liberty Wealth Management LLC now owns 1,234 shares of the company’s stock worth $42,000 after buying an additional 516 shares during the period. First PREMIER Bank lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 118.6% during the 4th quarter. First PREMIER Bank now owns 1,290 shares of the company’s stock worth $42,000 after buying an additional 700 shares during the period. Creative Financial Designs Inc. ADV bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 1st quarter worth approximately $67,000. Finally, GHP Investment Advisors Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 1st quarter worth approximately $72,000. 4.73% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA (Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Further Reading

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.